Valeant’s $930 Million Sale of iNova Pharmaceuticals, Business
June 8, 2017
Cleary Gottlieb is representing Goldman Sachs, as financial advisor to Valeant Pharmaceuticals International, Inc., in the sale of its iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash.
The deal signed on June 8, 2017, and is expected to close in the second half of 2017.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.